Dry powder inhaled ribavirin in healthy volunteers:  safety, tolerability, lung and systemic pharmacokinetics

S. Yang (Uxbridge, United Kingdom)

Source: International Congress 2017 – From microbiology to clinical work
Session: From microbiology to clinical work
Session type: Thematic Poster
Number: 4125
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Yang (Uxbridge, United Kingdom). Dry powder inhaled ribavirin in healthy volunteers:  safety, tolerability, lung and systemic pharmacokinetics. 4125

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012


Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers
Source: Eur Respir J 2006; 28: Suppl. 50, 332s
Year: 2006

Salmeterol pharmacokinetics following a 50-mcg dose by dry powder oral inhalation to healthy volunteers
Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma
Year: 2012


Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics
Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence
Year: 2021



Lung function, pharmacokinetics, and tolerability of indacaterol maleate and acetate in asthma patients
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019


Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Evaluation of safety, tolerability, pharmacokinetics, and food effect of Danirixin oral tablets in Japanese elderly healthy subjects
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018




Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans
Source: Eur Respir J 2006; 28: Suppl. 50, 661s
Year: 2006

Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Safety and pharmacokinetics of multiple-dose ciprofloxacin dry powder for inhalation in patients with moderate or severe COPD
Source: Annual Congress 2011 - Role of infection in exacerbations of COPD
Year: 2011

Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects
Source: Eur Respir J 2002; 20: Suppl. 38, 110s
Year: 2002

A multicompartmemt lung model predicts pulmonary pharmacokinetics of inhaled liposomal treprostinil (L606) in healthy volunteer
Source: Virtual Congress 2021 – Therapy of pulmonary hypertension
Year: 2021

A comparative study of the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol HFA and CFC MDI inhalers in healthy subjects
Source: Eur Respir J 2004; 24: Suppl. 48, 582s
Year: 2004

Pulmonary pharmacokinetics and safety of nebulised duramycin in healthy male volunteers
Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Year: 2009


Safety, efficacy and pharmacokinetics of inhaled TPI 1020 in smokers with asthma
Source: Annual Congress 2008 - New treatments for asthma
Year: 2008


Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008